Clinical trials in Pascani

Clinical research in Pascani is centered on cardiovascular diseases and nutritional and metabolic diseases, with studies recruiting patients for conditions linked to inflammation, heart function, and blood sugar control. These trials are exploring whether new treatments can improve outcomes for people with complex long-term illness.

• Heart failure with mildly reduced or preserved ejection fraction and related inflammation
• Atherosclerotic cardiovascular disease with chronic kidney disease and systemic inflammation
• Type 2 diabetes with inadequate glycaemic control

The main purpose of this research is to test whether emerging therapies can reduce cardiovascular events, improve heart-related outcomes, and strengthen control of metabolic disease.

One set of trials focuses on heart failure and the role of systemic inflammation, looking at whether a new treatment can better protect patients from serious heart-related complications compared with standard care.

• Heart failure with mildly reduced ejection fraction
• Heart failure with preserved ejection fraction
• Systemic inflammation as a key factor in disease progression

The research aims to improve treatment effectiveness for people whose heart failure is closely connected to inflammation.

Another trial area in this city examines type 2 diabetes, with a strong focus on lowering blood sugar and supporting better overall metabolic control in people who are not responding well enough to current treatment.

• Type 2 diabetes
• HbA1c improvement
• Metabolic management alongside standard diabetes care

The goal is to evaluate whether newer therapy options can outperform established treatment in helping patients achieve better glucose control.

Research also includes patients with established atherosclerotic cardiovascular disease and chronic kidney disease, especially when both are accompanied by ongoing inflammation. These studies are designed to see if a new approach can lower major cardiovascular risks more effectively than placebo-based standard care.

• Atherosclerotic cardiovascular disease
• Chronic kidney disease
• Systemic inflammation linked to higher cardiovascular risk

This work is aimed at reducing the risk of serious events such as heart attack, stroke, and cardiovascular death in high-risk patients.